Spectral Diagnostics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Toronto-based cardiac diagnostics company completes its offering of Special Convertible Securities. The offering will result in the issue of 1 mil. common shares of the stock and will net the firm $21.7 mil (at current exchange rates). First Marathon, Burns Fry, and Thomson Kernaghan are underwriting. Spectral plans to use the proceeds to fund its Point-of-Care line of cardiac diagnostics, which feature rapid format panel tests for diagnosing the cause of chest pain
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.